Gout: Causes and Treatment

Gout (colloquially: podagra, though that term strictly refers to a flare in the big toe joint) is the most common form of inflammatory arthritis in adults, particularly in men over 40 and in postmenopausal women. The disease results from the deposition of monosodium urate crystals in joints and periarticular tissues due to chronically elevated blood uric acid levels (hyperuricemia), triggering a sudden, intensely painful inflammatory reaction.

A typical first gout flare affects the metatarsophalangeal joint of the big toe (podagra in the strict sense), though it can also involve the knee, ankle, wrist, or elbow. Pain builds rapidly, often within a few hours, usually at night or in the early morning, accompanied by swelling, redness, and tenderness to touch severe enough that even the touch of bedsheets can be unbearable.

Uric acid is the end product of purine breakdown — compounds present both in the body's own cells (as a byproduct of normal cellular turnover) and in certain foods. Its blood concentration depends on the balance between production (including breakdown of dietary and naturally metabolized purines) and excretion, most of which happens through the kidneys. Hyperuricemia can result from increased uric acid production, decreased renal excretion, or — most often in clinical practice — a combination of both mechanisms, with impaired renal excretion being the dominant factor in most patients.

The goal of treating an acute gout flare differs from the goal of long-term therapy — it's about controlling pain and inflammation as quickly as possible, not lowering uric acid levels, a change in which during an acute flare can paradoxically worsen or prolong symptoms. Acute flares are treated with nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or glucocorticoids (oral, intra-articular, or intramuscular), depending on contraindications and patient preference — the effectiveness of these three drug classes is roughly comparable when used sufficiently early.

Urate-lowering therapy (ULT) is a long-term treatment whose goal is not only to prevent further flares but also to gradually dissolve already-deposited urate crystals and prevent permanent joint damage. The decision to start it, however, isn't automatic after every single flare.

A key element of the guidelines is the "treat-to-target" approach — the allopurinol dose (typically starting low, ≤100 mg/day, and gradually increasing, sometimes up to 800 mg/day) is adjusted progressively to reach a specific therapeutic target (usually a uric acid level below 6 mg/dl), rather than a single, fixed standard dose. A dose that's too low and never titrated is one of the more common causes of treatment failure in clinical practice.

Febuxostat, a newer urate-lowering drug with a different mechanism of action than allopurinol, was often promoted as an alternative for patients who couldn't tolerate allopurinol. A large cardiovascular safety trial, conducted at the request of the US FDA, provided data that significantly affected febuxostat's place in clinical practice.

Modifying diet is often the first, intuitive step after a gout diagnosis, but it's worth having realistic expectations about its effect: even a strict purine-restricted diet usually lowers uric acid levels only by a small, limited amount (on the order of 1 mg/dl), far less than effective pharmacotherapy. This doesn't mean diet is meaningless — changing eating habits alone can be significant for overall cardiovascular and metabolic risk, often elevated in gout patients, even if its impact on uric acid itself tends to be more modest than popular guides suggest.

A separate, popular topic in the context of diet and gout is cherries — specifically their association with reduced risk of flare recurrence — which we cover in more depth, along with a discussion of a specific case-crossover study, in our article on cherries and gout. It's worth treating as a supplement if you're specifically interested in that supplementation angle rather than the general clinical picture of the disease covered here.

Gout is a disease for which we now have genuinely good, evidence-based tools — from optimized colchicine dosing for an acute flare, through clear guidelines on when to start long-term therapy, to a large safety trial resolving the debate over which of the two main drugs to choose. Even so, in clinical practice, only single flares are still too often treated without addressing the underlying hyperuricemia, condemning patients to recurring, entirely avoidable episodes of pain.

If gout flares recur more than once or twice a year, it's worth treating that as a signal to talk to a doctor about long-term therapy, not just about another painkiller — the goal shouldn't be limited to surviving the current flare, but to making sure the next one never happens.